Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program

Back to Jobs

Compound has potential to benefit patients with severe hearing loss SAN DIEGO , Aug. 03, 2020 (GLOBE NEWSWIRE) — Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an exclusive license agreement with

Apply Now